About HIV

[sherlyk]

About HIV AIDS

* HIV can *never survive in any other liquid* medium also other than blood or semen (& please for God sake ... never in Pani Puri wala pani)

* Even if one drinks an HIV infected blood (or semen) of someone (ingest through Gastro Intestinal track), the virus can not survive in the acidic pH of stomach*. Highest extent of acidity is 0 (practically not possible) so imagine 1 as pH which is in our stomach. (This pH can burn your own finger in less than a second if you dip in that acid).


* Exposure of less than 1 second in AIR KILLS the HIV virus*(hence story of needle pricks in Cinema theatres is a crap). Even if blood from a wound (of infected person) dries up (*blood clot*), *the virus dies* and can not infect anyone else

* HIV transmission is *ONLY* an *INFECTION* i.e. entrance of virus in one's body. It *DOES NOT MEAN AIDS*.


* An HIV-infected person (after entrance of virus) can progress to a condition of AIDS only after *8 to 10 YEARS * (not in 15 days as in the Pani Puri story)

* It is *not HIV (virus) that kills a human* .....the virus attacks immune cells (cells that fight against foreign pathogens/antigens) and hence a person's ability to fight against infections & diseases slowly diminishes and person ultimately dies of a disease which could be as simple as TB

* Most importantly, HIV is no longer a dreadful disease ... it is "*CHRONIC MANAGEABLE DISEASE*" just like Diabetes or Hypertension.

* If there is anything you need to be careful from to prevent HIV is *Unsafe sex*, *Blood transfusion* (check before taking) / Blood donation (use sterilized needles only) and any *blood contact during an accident* or so where *amount of bleeding is very high.*


BizHat.com - Health

[proximity2]

The International AIDS Society-USA (IAS-USA) is a 501(c)(3) not-for-profit professional organization that has been sponsoring continuing medical education (CME) programs for physicians since 1992 and is accredited by the Accreditation Council for Continuing Medical Education (ACCME).
The International AIDS Society-USA has a clearly defined mission, an extensive network of experienced and committed HIV/AIDS experts, and is recognized for high-quality, independent educational programs. The primary educational and informational programs sponsored by the International AIDS Society-USA include CME Courses, Cases on the Web, development of Treatment Guidelines, and publication and distribution of Topics in HIV Medicine®.

The International AIDS Society-USA is not affiliated with worldwide IAS (an international organization of members working in HIV/AIDS).


Content Development and Objectivity Policies for CME Activities

The IAS-USA was founded on the commitment to produce Continuing Medical Education (CME) activities and services of the highest quality in the field of HIV/AIDS and that are absolutely free of commercial bias. All of the IAS-USA programs – such as conferences, Web-based CME publications, and treatment guidelines – are offered as part of a nationwide effort to inform HIV health care practitioners about the evolving challenges of caring for patients with HIV disease.

To further ensure complete independence of its program and content from commercial interests, the IAS-USA has adopted a policy that prohibits health care providers who participate in commercial marketing or promotional activities from being involved in IAS-USA programs and activities. Information about the policy on the separation of promotional and marketing activities from IAS–USA CME activities, adopted in January 2009, can be found here.

The excellence of the IAS-USA programs is driven by a broad faculty of clinicians and researchers who are experts in HIV/AIDS and by the organization’s volunteer board of directors. The board and faculty determine issues that are most relevant to the clinical management of patients and guide the development of program content. New faculty members are screened by the IAS-USA in order to promote a diversity of clinical views.

The IAS-USA strives to maintain an objective, balanced, and scientifically rigorous program that is free from commercial bias. Funding for some organization programs may originate from educational grants from commercial companies or from Federal agencies. For CME activities that are designated to receive commercial support, the IAS-USA adheres to the following policies that prevent the involvement of outside entities in the planning and provision of program content:
Commercially supported programs do not receive funding from a single source; funds must be received from several companies with competing products, and is pooled to be used at IAS-USA discretion.
The IAS-USA maintains a firewall between commercial funding sources and CME program content by internally managing every aspect of the planning, development, and delivery of its CME activities.
The IAS-USA requires full disclosure of relationships—financial and otherwise—that its faculty or other persons in control of content with commercial organizations and other outside entities.
When a real or potential conflict of interest is determined to exist, the IAS-USA resolves the conflict before permitting a faculty member to participate in CME program development or implementation.
Finally, the IAS-USA undertakes an independent peer review of the content and recommendations of all of its CME activities.

Click here to view the 2008 Summary of Programs


2010 Funders

Commercial Companies

Substantial Grant Support
Merck & Co, Inc
Tibotec Therapeutics

Bristol-Myers Squibb
Gilead Sciences, Inc

Generous Grant Support
Viiv Healthcare


ACCME Accreditation

The IAS-USA is accredited by the Accreditation Council for Continuing Medical Education to sponsor continuing medical education for physicians.

In 2006, the IAS-USA received Accreditation with Commendation, joining an elite group of organizations in the United States that have been awarded this prestigious status "reserved for programs which are truly exceptional," according to the ACCME.


Future Directions

A primary challenge in the field of HIV/AIDS education lies in disseminating the most recent information and treatment guidelines to physicians while knowledge continues to evolve. The IAS-USA is committed to pursuing the most effective, convenient, and cost-efficient ways to reach a greater proportion of the target physician audience and effect long-term improvements in physicians' clinical care of their patients.

Until there is a cure for HIV disease, the IAS-USA will continue to provide information and education for physicians involved in the treatment of HIV/AIDS. Our goal is to help physicians provide the best possible care for their patients and, therefore, positively impact patient lives.
__________________________________________________ _________
Teeth Bleaching Glasgow| Invisalign Glasgow
--

[sherlyk]

U.S. scientists create HIV resistant cells

American scientists have created HIV-resistant cells that could one day pave the way for controlling the virus without using harsh anti-retroviral drugs.

Scientists at the Keck School of Medicine, at the University of Southern California, used mice to test the cells that target one of the two “gateway” molecules that the Human Immunodeficiency Virus (HIV) uses to enter human cells, Meghan Lewit, spokeswoman for the team of researchers, said.

The researchers modified blood stem cells to make them resistant to HIV and then transplanted them into the mice, enabling the rodents to control the infection.

If the approach can be applied to humans, it could enable a long-term generation of HIV-resistant cells in the body, providing the potential for the patient’s cells to suppress HIV, Ms. Lewit said.

“This hybrid gene and stem cell therapy show that it is possible to create HIV-resistant immune cells that can eventually win the battle against HIV,” Paula Cannon, principal investigator and associate professor of molecular microbiology and immunology, was quoted as saying by Xinhua.

“We’ve done it at the scale of a mouse, and the challenge now is to see if this can be done at the scale of a human patient.”

“The strategy arose from the observation that people with a mutation in a gene called CCR5 are naturally resistant to infection with the most common strains of HIV and do not develop AIDS,” Ms. Lewit said.

Researchers used enzymes to knock out the CCR5 gene in human blood stem cells, and then transplanted the modified stem cells into mice, Ms. Lewit said.

The cells developed into mature cells of the human immune system, including the T cells that HIV infects. And when they infected the mice with HIV, the animals were able to maintain normal levels of the human T cells and suppress HIV.

“By engineering CCR5—deficient stem cells, we may allow a patient to produce HIV-resistant cells in all of the cell types that the virus infects, and for long periods of time,” Ms. Cannon said.

“If successful, it could one day allow patients to control their HIV without needing to take anti-retroviral drugs.”

BizHat.com - Health